Skill Guide

Experimental design and power analysis for longevity intervention studies

The systematic process of structuring preclinical and clinical trials to test longevity interventions (e.g., drugs, supplements, lifestyle changes) with statistically valid sample sizes and effect detection capabilities.

This skill is critical for translating geroscience hypotheses into viable therapeutic pipelines, directly impacting R&D cost efficiency and de-risking multi-million dollar investments in drug development.

1 Careers

1 Categories

9.2 Avg Demand

15% Avg AI Risk

How to Learn Experimental design and power analysis for longevity intervention studies

Focus on core statistical principles: understanding Type I/II errors, p-values, and confidence intervals. Learn the key outcome measures in longevity studies (lifespan, healthspan, frailty indices, biomarkers of aging like DNA methylation clocks).

Move to application: use software to run power calculations for different study designs (parallel, crossover, adaptive). Master the challenge of defining a 'clinically significant' effect size for aging, where the natural history data is often limited.

Design integrated multi-arm, multi-stage (MAMS) trials that can test multiple interventions or doses simultaneously. Develop expertise in Bayesian adaptive designs that allow for continuous learning and sample size re-estimation during the trial, a major efficiency gain for long-duration aging studies.

Practice Projects

Beginner

Project

Power Analysis for a Simple Lifespan Assay

Scenario

You are tasked with designing a mouse lifespan study to test a novel compound. You need to determine how many mice per group are required to detect a 10% increase in median lifespan with 80% power.

How to Execute

1. Gather historical control group survival data (e.g., median lifespan, hazard rate). 2. Use a survival analysis power calculator (e.g., in R or Python) to input the expected hazard ratio (HR=0.9 for a 10% effect). 3. Adjust alpha (typically 0.05) and power (0.8) to calculate the required sample size. 4. Write a short report justifying your sample size to a non-statistician PI.

Intermediate

Project

Designing a Clinical Trial for a Senolytic Therapy

Scenario

A biotech is planning a Phase II trial for a senolytic drug aimed at improving physical function in older adults with frailty. The primary endpoint is the Short Physical Performance Battery (SPPB) score at 6 months.

How to Execute

1. Conduct a literature review to find the minimal clinically important difference (MCID) and standard deviation for SPPB in the target population. 2. Use a two-sample t-test power calculator to determine sample size per arm. 3. Factor in expected attrition (e.g., 20% dropout rate over 6 months) to inflate the initial recruitment target. 4. Propose a stratified randomization scheme by baseline frailty level to ensure balance.

Advanced

Case Study/Exercise

Rescuing an Underpowered Intervention Study

Scenario

Midway through a 2-year mouse healthspan study, a safety review shows the control group's health metrics are degrading faster than historical data suggested, making the planned analysis for the primary endpoint (a composite healthspan score) hopelessly underpowered.

How to Execute

1. Perform a blinded interim power re-estimation based on the observed variance and event rates. 2. Propose an adaptive design amendment to the oversight board: add a new, higher-dose treatment arm and modify the primary endpoint to a more sensitive, individual biomarker. 3. Re-calculate the sample size for the new design, justifying the additional cost. 4. Present a revised statistical analysis plan (SAP) that pre-specifies these changes to maintain trial integrity.

Tools & Frameworks

Statistical Software & Packages

R (survival, pwr, rpact packages)Python (lifelines, statsmodels.stats.power)G*PowerPASS (NCSS)

Used for performing power and sample size calculations for various experimental designs (t-tests, ANOVA, survival analysis, mixed models). R and Python are preferred for reproducibility and integration into analysis pipelines; commercial software like PASS offers extensive templates.

Mental Models & Methodologies

Adaptive Trial Design FrameworkBayesian Decision-MakingMinimal Clinically Important Difference (MCID)Intention-to-Treat (ITT) vs. Per-Protocol Analysis

The Adaptive Design Framework is crucial for managing long, costly aging studies by allowing pre-planned modifications. Bayesian methods enable continuous learning. MCID grounds the statistical effect size in clinical reality. ITT analysis is the gold standard for preventing bias in RCTs.

Interview Questions

Answer Strategy

Demonstrate a structured approach, not just a number. Use a formal power analysis framework: state the hypotheses, specify the alpha and power, select the correct statistical test (e.g., log-rank test for survival data), and justify the assumed effect size and variance. Mention practical considerations like attrition. Sample answer: 'I'd use a survival analysis power calculation, assuming a hazard ratio derived from the median difference. I'd set alpha at 0.05 (two-sided) and power at 0.8, using the historical variance to estimate the required events. I'd then inflate the starting cohort by 15-20% to account for unexpected deaths during the run-in period, ensuring we have enough animals to detect that 2-month difference with high confidence.'

Answer Strategy

This tests adaptive thinking and ethical rigor. The answer should reference a specific pre-specified rule or a formally proposed amendment. Highlight balancing scientific validity (preventing bias) with ethical responsibility (not wasting resources or exposing subjects to unnecessary risk). Sample answer: 'In a frailty intervention trial, interim analysis showed significantly higher variance in our primary endpoint than anticipated. I convened the DSMB and, using our pre-specified adaptive design allowance, proposed re-estimating the sample size upward. The ethical imperative was to avoid conducting an underpowered study that would be uninformative, while the statistical method ensured we preserved the trial's Type I error rate through closed testing procedures.'